Close Menu

NEW YORK – Sense Biodetection is accelerating the development of an instrument-free molecular platform for SARS-CoV-2, the coronavirus that causes COVID-19, in a bid to provide more sensitive point-of-care tests in the market.  

If successful, the company could have the device available for sale to hospitals, physicians' offices, clinical pharmacies, and community healthcare centers in a few months, said Sense Bio's CEO Harry Lamble.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.